Wedbush last night initiated coverage of Perspective Therapeutics with an Outperform rating and $25 price target The firm believes Perspective can advance the radiopharmaceutical landscape with its lead212-based programs. The programs should generate “differentiated” efficacy and safety profiles compared to agents utilizing lutetium and actinium, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics initiated with an Outperform at Wedbush
- GM, Ford and Rivian downgraded: Wall Street’s top analyst calls
- Perspective Therapeutics initiated with a Buy at Truist
- Perspective Therapeutics presents at World Molecular Imaging Congress
- Perspective Therapeutics granted Fast Track Designation for VMT01